Aptorum Group shares surge 10.67% premarket as DiamiR collaborates with INB to validate automated APOE testing platform for Alzheimer’s diagnostics.

Aptorum Group surged 10.67% in premarket trading following news of a collaboration between its subsidiary DiamiR Biosciences and Instant NanoBiosensors (INB) to validate INB’s automated APOE testing platform. The partnership aims to enhance Alzheimer’s disease risk assessment by evaluating INB’s technology for clinical use within DiamiR’s certified laboratory. This development aligns with Aptorum’s ongoing merger with DiamiR, expected to close in 2026, and highlights progress in expanding diagnostic capabilities for neurological conditions. The validation of a scalable, automated testing solution could strengthen market confidence in the combined entity’s ability to address unmet medical needs, directly supporting its strategic and financial outlook.